CUE — Cue Biopharma Cashflow Statement
0.000.00%
- $37.43m
- $13.65m
- $5.49m
- 27
- 18
- 25
- 13
Annual cashflow statement for Cue Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -36.7 | -44.8 | -44.2 | -53 | -50.7 |
Depreciation | |||||
Non-Cash Items | 9.42 | 10 | 8.56 | 9.53 | 11.6 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -4.33 | 1.24 | -4.49 | 0.751 | -1.36 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -30.8 | -32.5 | -38.8 | -41.8 | -40 |
Capital Expenditures | -0.046 | -0.595 | -0.913 | -0.171 | 0 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 3.49 | 5.05 | 10 | -24.4 | 25 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 3.45 | 4.46 | 9.11 | -24.6 | 25 |
Financing Cash Flow Items | 0 | 0 | 0 | -0.142 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 50.8 | 58.6 | 19.2 | 53.7 | 11.9 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 23.4 | 30.6 | -10.5 | -12.8 | -3.1 |